Assembly Biosciences PFO granted 3,500 RSUs

Assembly Biosciences, Inc. reported that its Principal Financial Officer and Principal Accounting Officer, Jeanette M. Bjorkquist, acquired 3,500 shares of common stock at no cost through a grant of restricted stock units.

Rhea-AI Filing Summary

Assembly Biosciences, Inc. reported that its Principal Financial Officer and Principal Accounting Officer, Jeanette M. Bjorkquist, acquired 3,500 shares of common stock at no cost through a grant of restricted stock units. These RSUs represent 35% of her annual equity grant and became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan that increased the shares authorized under the plan. The RSUs vest in four approximately equal installments on March 29 of each year from 2027 through 2030, assuming she remains in continuous service. Following this grant, Bjorkquist directly holds 14,589 shares of common stock.

Insider Trade Summary

Grant/Award: 3,500 shares

Grant/Award 1 txn

Insider Bjorkquist Jeanette M

Role PFO and PAO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,500	$0.00	$0.00

Holdings After Transaction: Common Stock — 14,589 shares (Direct)

Footnotes (1)

1. F1. Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026 and was contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increased the number of shares of common stock authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted on March 29, 2026, the RSUs became issuable upon stockholder approval of the Plan Amendment on June 4, 2026 and vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030.

Key Figures

RSU grant size: 3,500 shares Grant price: $0.00 per share Shares held after grant: 14,589 shares +3 more

6 metrics

RSU grant size 3,500 shares Restricted stock units granted as 35% of annual equity award

Grant price $0.00 per share Compensation grant, not open-market purchase

Shares held after grant 14,589 shares Direct holdings following the reported transaction

Vesting start date March 29, 2027 First of four approximately equal vesting installments

Final vesting date March 29, 2030 Last scheduled vesting installment for the RSUs

Plan approval date June 4, 2026 Stockholders approved amendment increasing shares under 2018 Plan

Key Terms

Restricted stock units ("RSUs"), annual equity grant, Amended and Restated 2018 Stock Incentive Plan, Plan Amendment, +1 more

5 terms

Restricted stock units ("RSUs") financial

"Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

annual equity grant financial

"RSUs representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026..."

Amended and Restated 2018 Stock Incentive Plan financial

"an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan")..."

Plan Amendment financial

"the Plan Amendment that increased the number of shares of common stock authorized for issuance..."

continuous service financial

"vest in four approximately equal installments, assuming continuous service on each vesting date..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Assembly Biosciences (ASMB) disclose in this Form 4 for Jeanette Bjorkquist?

Assembly Biosciences disclosed that PFO and PAO Jeanette M. Bjorkquist received a grant of 3,500 restricted stock units at no cost. These RSUs are part of her annual equity compensation and convert into common shares as they vest over time.

How many Assembly Biosciences (ASMB) shares were granted to Jeanette Bjorkquist?

Jeanette Bjorkquist was granted 3,500 shares of Assembly Biosciences common stock via restricted stock units. The grant price was zero because it is compensation, not a market purchase, and the shares deliver as the RSUs vest in future years.

When do Jeanette Bjorkquist’s Assembly Biosciences (ASMB) RSUs vest?

The RSUs vest in four installments on March 29, 2027, 2028, 2029, and 2030. Each installment is approximately equal, and vesting requires Ms. Bjorkquist to maintain continuous service with Assembly Biosciences through each scheduled vesting date.

What shareholder approval was required for this Assembly Biosciences (ASMB) equity grant?

The RSU grant was contingent on stockholder approval of an amendment to Assembly Biosciences’ Amended and Restated 2018 Stock Incentive Plan. The amendment increased the number of shares authorized under the plan and was approved on June 4, 2026, making the RSUs issuable.

How many Assembly Biosciences (ASMB) shares does Jeanette Bjorkquist hold after this transaction?

After the RSU grant, Jeanette M. Bjorkquist directly holds 14,589 shares of Assembly Biosciences common stock. This figure reflects her position following the 3,500-share award reported in the Form 4 insider transaction filing.

Is the Assembly Biosciences (ASMB) Form 4 a market purchase or compensation grant?

This Form 4 reflects a compensation grant, not a market purchase. The 3,500 shares were acquired at a price of $0.00 per share via restricted stock units granted under the company’s stock incentive plan, subject to time-based vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bjorkquist Jeanette M

(Last) (First) (Middle)

C/O ASSEMBLY BIOSCIENCES, INC.

TWO TOWER PLACE, 7TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PFO and PAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/29/2026		A		3,500(1)	A	$0	14,589	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026 and was contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increased the number of shares of common stock authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted on March 29, 2026, the RSUs became issuable upon stockholder approval of the Plan Amendment on June 4, 2026 and vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030.

	/s/ John O. Gunderson, as Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)